• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 的动态异质性:数学模型的启示。

Dynamic heterogeneity in COVID-19: Insights from a mathematical model.

机构信息

Department of Radiation Oncology, Edwin L Steele Laboratories, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America.

Department of Mechanical and Manufacturing Engineering, Cancer Biophysics Laboratory, University of Cyprus, Nicosia, Cyprus.

出版信息

PLoS One. 2024 May 31;19(5):e0301780. doi: 10.1371/journal.pone.0301780. eCollection 2024.

DOI:10.1371/journal.pone.0301780
PMID:38820409
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11142552/
Abstract

Critical illness, such as severe COVID-19, is heterogenous in presentation and treatment response. However, it remains possible that clinical course may be influenced by dynamic and/or random events such that similar patients subject to similar injuries may yet follow different trajectories. We deployed a mechanistic mathematical model of COVID-19 to determine the range of possible clinical courses after SARS-CoV-2 infection, which may follow from specific changes in viral properties, immune properties, treatment modality and random external factors such as initial viral load. We find that treatment efficacy and baseline patient or viral features are not the sole determinant of outcome. We found patients with enhanced innate or adaptive immune responses can experience poor viral control, resolution of infection or non-infectious inflammatory injury depending on treatment efficacy and initial viral load. Hypoxemia may result from poor viral control or ongoing inflammation despite effective viral control. Adaptive immune responses may be inhibited by very early effective therapy, resulting in viral load rebound after cessation of therapy. Our model suggests individual disease course may be influenced by the interaction between external and patient-intrinsic factors. These data have implications for the reproducibility of clinical trial cohorts and timing of optimal treatment.

摘要

危重病,如严重的 COVID-19,在表现和治疗反应上存在异质性。然而,仍有可能是由于动态和/或随机事件的影响,导致即使接受相似治疗的相似患者也可能遵循不同的病程。我们开发了一种 COVID-19 的机械数学模型,以确定 SARS-CoV-2 感染后可能出现的各种临床病程,这些病程可能源于病毒特性、免疫特性、治疗方式和随机外部因素(如初始病毒载量)的特定变化。我们发现,治疗效果和基线患者或病毒特征并不是结果的唯一决定因素。我们发现,增强的先天或适应性免疫反应可能导致病毒控制不良、感染消退或非传染性炎症损伤,具体取决于治疗效果和初始病毒载量。即使有效控制了病毒,低氧血症也可能是由于病毒控制不良或持续炎症引起的。适应性免疫反应可能会被早期有效的治疗抑制,导致治疗停止后病毒载量反弹。我们的模型表明,个体疾病过程可能受到外部因素和患者内在因素之间相互作用的影响。这些数据对临床试验队列的可重复性和最佳治疗时机具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/7ede5b7e6770/pone.0301780.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/4f54b2d4a4f0/pone.0301780.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/34cf35f9f38e/pone.0301780.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/b0ce815fc9cb/pone.0301780.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/201a08a51491/pone.0301780.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/f0e270bbad17/pone.0301780.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/7ede5b7e6770/pone.0301780.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/4f54b2d4a4f0/pone.0301780.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/34cf35f9f38e/pone.0301780.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/b0ce815fc9cb/pone.0301780.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/201a08a51491/pone.0301780.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/f0e270bbad17/pone.0301780.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4522/11142552/7ede5b7e6770/pone.0301780.g006.jpg

相似文献

1
Dynamic heterogeneity in COVID-19: Insights from a mathematical model.COVID-19 的动态异质性:数学模型的启示。
PLoS One. 2024 May 31;19(5):e0301780. doi: 10.1371/journal.pone.0301780. eCollection 2024.
2
Mathematical modeling of interaction between innate and adaptive immune responses in COVID-19 and implications for viral pathogenesis.COVID-19 中先天免疫和适应性免疫反应相互作用的数学建模及其对病毒发病机制的影响。
J Med Virol. 2020 Sep;92(9):1615-1628. doi: 10.1002/jmv.25866. Epub 2020 May 13.
3
Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.《COVID-19 中的每日病毒动力学和固有及适应性免疫反应评估:病例系列》。
mSphere. 2020 Nov 11;5(6):e00827-20. doi: 10.1128/mSphere.00827-20.
4
Different Innate and Adaptive Immune Responses to SARS-CoV-2 Infection of Asymptomatic, Mild, and Severe Cases.无症状、轻症和重症 SARS-CoV-2 感染者的固有和适应性免疫反应不同。
Front Immunol. 2020 Dec 16;11:610300. doi: 10.3389/fimmu.2020.610300. eCollection 2020.
5
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验(SAINT)评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力:一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
6
Heterogeneous SARS-CoV-2 kinetics due to variable timing and intensity of immune responses.由于免疫反应的时间和强度不同,导致 SARS-CoV-2 的异质性动力学。
JCI Insight. 2024 Apr 4;9(9):e176286. doi: 10.1172/jci.insight.176286.
7
Modeling the viral dynamics of SARS-CoV-2 infection.模拟 SARS-CoV-2 感染的病毒动力学。
Math Biosci. 2020 Oct;328:108438. doi: 10.1016/j.mbs.2020.108438. Epub 2020 Aug 6.
8
SARS-CoV-2 innate effector associations and viral load in early nasopharyngeal infection.SARS-CoV-2 先天效应因子关联与早期鼻咽感染中的病毒载量。
Physiol Rep. 2021 Feb;9(4):e14761. doi: 10.14814/phy2.14761.
9
Divergent COVID-19 Disease Trajectories Predicted by a DAMP-Centered Immune Network Model.由 DAMP 为中心的免疫网络模型预测的 COVID-19 疾病轨迹分化。
Front Immunol. 2021 Oct 28;12:754127. doi: 10.3389/fimmu.2021.754127. eCollection 2021.
10
Immune-viral dynamics modeling for SARS-CoV-2 drug development.SARS-CoV-2 药物开发的免疫-病毒动力学建模。
Clin Transl Sci. 2021 Nov;14(6):2348-2359. doi: 10.1111/cts.13099. Epub 2021 Jul 8.

引用本文的文献

1
A novel approach to estimating through infection networks: understanding regional transmission dynamics of COVID-19.一种通过感染网络进行估算的新方法:了解新冠病毒病的区域传播动态
Front Public Health. 2025 Jun 18;13:1586786. doi: 10.3389/fpubh.2025.1586786. eCollection 2025.
2
Biomarkers of mRNA vaccine efficacy derived from mechanistic modeling of tumor-immune interactions.源自肿瘤免疫相互作用机制模型的mRNA疫苗疗效生物标志物。
PLoS Comput Biol. 2025 Jun 12;21(6):e1013163. doi: 10.1371/journal.pcbi.1013163. eCollection 2025 Jun.
3
Mathematical modeling of impacts of patient differences on renin-angiotensin system and applications to COVID-19 lung fibrosis outcomes.

本文引用的文献

1
Modeling how antibody responses may determine the efficacy of COVID-19 vaccines.模拟抗体反应如何决定新冠疫苗的疗效。
Nat Comput Sci. 2022 Feb;2(2):123-131. doi: 10.1038/s43588-022-00198-0. Epub 2022 Feb 28.
2
A mathematical model of SARS-CoV-2 immunity predicts paxlovid rebound.SARS-CoV-2 免疫的数学模型预测帕罗韦德(paxlovid)反弹。
J Med Virol. 2023 Jun;95(6):e28854. doi: 10.1002/jmv.28854.
3
Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2.
患者差异对肾素-血管紧张素系统影响的数学建模及其在COVID-19肺纤维化结局中的应用
Comput Biol Med. 2025 Mar;186:109631. doi: 10.1016/j.compbiomed.2024.109631. Epub 2025 Jan 2.
用于评估健康、癌症和免疫抑制患者感染 SARS-CoV-2 时加强针效果的机制模型。
Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2211132120. doi: 10.1073/pnas.2211132120. Epub 2023 Jan 9.
4
Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States, April-September 2022.帕克洛维德降低 COVID-19 成年患者住院率-美国,2022 年 4 月-9 月。
MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1531-1537. doi: 10.15585/mmwr.mm7148e2.
5
Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.奈玛特韦-利托那韦与新冠病毒感染中的病毒载量反弹
N Engl J Med. 2022 Sep 15;387(11):1047-1049. doi: 10.1056/NEJMc2205944. Epub 2022 Sep 7.
6
Protection Associated with Previous SARS-CoV-2 Infection in Nicaragua.尼加拉瓜既往感染新型冠状病毒2的相关保护作用。
N Engl J Med. 2022 Aug 11;387(6):568-570. doi: 10.1056/NEJMc2203985. Epub 2022 Jul 20.
7
Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5.SARS-CoV-2 奥密克戎亚变种 BA.2.12.1、BA.4 和 BA.5 的抗体逃逸
Nature. 2022 Aug;608(7923):603-608. doi: 10.1038/s41586-022-05053-w. Epub 2022 Jul 5.
8
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum.奥密克戎 BA.4 和 BA.5 对疫苗和 BA.1 血清的抗体逃逸。
Cell. 2022 Jul 7;185(14):2422-2433.e13. doi: 10.1016/j.cell.2022.06.005. Epub 2022 Jun 9.
9
Modeling recapitulates the heterogeneous outcomes of SARS-CoV-2 infection and quantifies the differences in the innate immune and CD8 T-cell responses between patients experiencing mild and severe symptoms.建模再现了 SARS-CoV-2 感染的异质结果,并量化了轻症和重症患者之间固有免疫和 CD8 T 细胞反应的差异。
PLoS Pathog. 2022 Jun 27;18(6):e1010630. doi: 10.1371/journal.ppat.1010630. eCollection 2022 Jun.
10
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.严重急性呼吸综合征冠状病毒2型奥密克戎亚变体BA.2.12.1、BA.4和BA.5的中和逃逸
N Engl J Med. 2022 Jul 7;387(1):86-88. doi: 10.1056/NEJMc2206576. Epub 2022 Jun 22.